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Summary. The effect of in vivo chronic administration 
of recombinant human growth hormone (rhGH) on 
morphology and individual GH release in somatotroph 
cells was evaluated in young male Wistar rats. Over an 
18-day period, 30-day-old male rats were injected daily 
with 1.5 1U rhGH/kg (GPG group) or saline (VPG 
group) by subcutaneous injection. Electron-immuno- 
cytochemical, ultrastructural and morphometric studies 
of somatotroph cells were carried out. Additionally, rat 
pituitary cells were dispersed and overall and individual 
GH release was studied by radioimmunoassay and cell 
immunoblot assay (quantified by image analysis), 
respectively. The ultrastructure and size of somatotroph 
cells did not change, but volume density of secretion 
granules was reduced (pc0.01) by previous in vivo GH 
treatment. At four days, basal GH release of rat pituitary 
cell monolayer cultures was lower in the GPG group 
than in the VPG group (pc0.05); after 12  hours of 
culture, GHRH stimulation of GH release was lower in 
the GPG group than in the VPG group (p<0.05), and 
GHRH+SRIH inhibited GH release in the GPG group 
(p<0.05), but not in the VPG group. The percentage of 
somatotroph cells was not modified, but the ratio of 
strongly/weakly GH-immunostained cells had changed; 
weakly GH-immunostained cells increased from 34% to 
55%. Moreover, in vitro treatment with GHRH, SRIH, 
and both, easily changed the strongly/weakly GH- 
immunostained cell ratio. Individual GH release, 
however, was not changed by previous in vivo GH 
treatment, although GHRH preferably stimulated a 
subpopulation of GH cells and SRIH did not inhibit 
individual GH release. These data suggest that 
exogenous chronic rhGH treatment down-regulates 
somatotroph function by modifying the proportion of 
GH cell subpopulation. 
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Introduction 
It is widely recognised that growth hormone (GH) 
administration leads to a decrease in the subsequent 
response of GH to GH releasing hormone (GHRH) and 
other stimuli (Nakamoto et al., 1986; Rosenthal et al., 
1986; Ross et al., 1987). This appears to be a direct 
effect of GH and not of IGF-1 (Minami et al., 1997), 
mediated by an increase in hypothalamic somatostatin 
secretion (SRIH) (Sheppard et al., 1978; Burton et al., 
1992) and a decrease in hypothalamic GHRH release 
(Conway et al., 1985; Aguila and McCann 1993; 
Bertherat et al., 1993). The presence of GH-receptor 
mRNA in pituitary cells, such as somatotropes, lacto- 
tropes and gonadotropes (Harvey et al., 1993), suggests 
that GH acts directly on these cells through paracrine or 
autocrine mechanisms. 
The feedback mechanism that results from the 
exogenous administration of GH determines a decrease- 
suppression of GH response to GHRH in a dose- 
dependent fashion (Clark et al., 1988), lasting for at least 
4 hours (Lanzi and Tannenbaum, 1992a). As a result of 
SRIH inhibition of GH secretion, GH is stored in the cell 
for a period of time after which the GHRH stimulus 
produces an even greater GH response from the 
somatotroph cells (Lanzi and Tannenbaum, 1992b). On 
the other hand, suppression of hypothalamic GHRH 
release (Sato and Frohman, 1993; Uchiyama et al., 1994) 
results in a decrease in the amount of GH that can be 
released by each somatotroph cell (Matteri et al., 
1997). It can therefore be expected that, following 
administration of exogenous GH, the morphology of the 
somatotroph cells will be modified. 
Kurosumi (1986) described three types of somato- 
troph cells in the rat, based on their ultrastructural 
features: type I somatotroph cell containing 350 nm 
secretion granules; type I1 somatotroph cell containing 








